Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a report published on Tuesday morning,Benzinga reports. They currently have a $9.00 target price on the stock.

Separately, D. Boral Capital lifted their price objective on Lineage Cell Therapeutics from $2.00 to $3.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $6.00.

Lineage Cell Therapeutics Trading Up 0.7%

Shares of Lineage Cell Therapeutics stock opened at $1.48 on Tuesday. The stock has a market capitalization of $368.65 million, a price-to-earnings ratio of -5.29 and a beta of 1.74. The firm’s 50-day moving average price is $1.70 and its two-hundred day moving average price is $1.69. Lineage Cell Therapeutics has a 1-year low of $0.37 and a 1-year high of $2.09.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last posted its earnings results on Thursday, March 5th. The company reported $0.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.07. The company had revenue of $6.61 million during the quarter, compared to analysts’ expectations of $1.96 million. Lineage Cell Therapeutics had a negative net margin of 436.47% and a negative return on equity of 76.13%. As a group, equities research analysts predict that Lineage Cell Therapeutics will post -0.12 EPS for the current year.

Institutional Trading of Lineage Cell Therapeutics

Several hedge funds have recently modified their holdings of LCTX. SG Americas Securities LLC acquired a new stake in shares of Lineage Cell Therapeutics in the fourth quarter valued at approximately $25,000. Citizens Financial Group Inc. RI acquired a new position in Lineage Cell Therapeutics during the 3rd quarter worth $25,000. Define Financial LLC bought a new position in Lineage Cell Therapeutics in the 4th quarter valued at $33,000. DLD Asset Management LP bought a new position in Lineage Cell Therapeutics in the 4th quarter valued at $33,000. Finally, Kestra Advisory Services LLC increased its stake in shares of Lineage Cell Therapeutics by 174.7% in the 4th quarter. Kestra Advisory Services LLC now owns 27,747 shares of the company’s stock valued at $46,000 after buying an additional 17,647 shares during the period. 62.47% of the stock is owned by institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.